Bavarian Drops RSV Program After Phase III Flop

Shifts Focus To Chikungunya

 
• By Ayisha Sharma

The Danish firm’s respiratory syncytial vaccine disappointed in a Phase III trial, marking an unexpected setback after a year of mpox-related successes, prompting all eyes to turn towards a recently-acquired chikungunya vaccine program.  

neon red exit sign against sunset sky
Bavarian Is Leaving The RSV Space After An Unexpected Disappointment • Source: Shutterstock

More from Clinical Trials

More from R&D